Termination of Early Pregnancy in Scarred Uterus With Lletrozole and Misoprostol Compared to Misoprostol Alone

Termination of Early Pregnancy in Scarred Uterus With Letrozole and Misoprostol Compared to Misoprostol Alone

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05067309

Enrollment

Registered

2021-10-05

Start date

2021-10-01

Completion date

2022-08-01

Last updated

2021-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Termination of Early Pregnancy in Scarred Uterus

Brief summary

Termination of early pregnancy in scarred uterus with letrozole and misoprostol compared to Misoprostol alone

Interventions

DRUGLetrozole 2.5mg

Missed abortion received letrozole then misoprostol

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Inclusion criteria

* Minimum age of 18 years for mother. * Non-viable fetus (missed abortion or blighted ovum) in the 1st trimester of pregnancy evidenced by criteria for diagnosis by TVS . * Previous C.S or Myomectomy (1 or more ) * lack of any maternal diseases such as: heart disease, asthma, history of thromboembolism, cancer, renal failure, and liver diseases.

Exclusion criteria

* \* Medical problem in patient * Emergency conditions which need intervention . * History of allergy to misoprostol or letrozole drugs.

Design outcomes

Primary

Measure	Time frame	Description
Complete abortion of early pregnancy with letrozole then misoprostol	6 months	Letrozole increase cervical ripening

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026